Abstract
Intermittent and low-dose parathyroid hormone (PTH) injection to stimulate bone formation has been used in the treatment of osteoporosis. The N-terminal fragment 1–34 of PTH is quite similar in structure and function to N-terminal PTH-related protein (PTHrP). PTH(1–34) and PTHrP also share a coreceptor, the PTH/PTHrP receptor. Therefore, some studies have suggested that PTHrP could effectively stimulate bone formation, similar to PTH. We used an ovariectomized (OVX) rat model of osteoporosis to study the effects of PTHrP(1–34) on bone metabolism by measuring bone mineral density (BMD), bone histomorphometrics, and biomechanical parameters. We found that subcutaneous injection of PTHrP(1–34) (40 or 80 μg/kg body weight every day) in OVX rats increased lumbar and femoral BMD, improved bone biomechanical properties, enhanced bone strength, and promoted bone formation. We selected 40 μg/kg as the preferred therapeutic dose of PTHrP(1–34) and investigated the effects of frequency of treatment (per 1, 2, 3, or 7 days) on bone metabolism in OVX rats. We found that injection of PTHrP(1–34) once per day or every other day significantly improved the BMD and strength of OVX rats. Serum calcium and phosphate levels in all treated rats did not vary significantly from control rats. Based on our results, intermittent low-dose PTHrP(1–34) injection promoted bone formation in OVX rats, suggesting a high potential for therapeutic use in osteoporosis patients.
Similar content being viewed by others
Abbreviations
- BMD:
-
Bone mineral density
- DTS:
-
Double-labeled surface in total trabecular bone surface
- MAR:
-
Mineral apposition rate
- ObS:
-
Osteoblast surface
- OcS:
-
Osteoclast surface
- OVX:
-
Ovariectomized
- PTH:
-
Parathyroid hormone
- PTHrP:
-
Parathyroid hormone-related protein
- STS:
-
Single-labeled surface in total trabecular bone surface
- TBV/TTV:
-
Total bone volume/total tissue volume
References
Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175–191
Nguyen TV, Center JR, Eisman JA (2000) Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology study. Maturitas 36(1):27–34
Rosen CJ, Bilezikian JP (2001) Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 86:957–964
Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, Lindsay R (2001) Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Metab 16:925–931
Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441
Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetić K, Müller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 16:1846–1853
Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129–2134
Poynton AR, Lane JM (2002) Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 27(16 suppl 1):s40–s48
Whitfield JF (2006) Parathyroid hormone: a novel tool for treating bone marrow depletion in cancer patients caused by chemotherapeutic drugs and ionizing radiation. Cancer Lett 244:8–15
Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA (2013) Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1–31)NH(2)] in postmenopausal women with osteoporosis. Bone 53:160–166
Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM (2000) Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15:1517–1525
Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF (2003) Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:569–575
Burtis WJ, Wu T, Bunch C, Wysolmerski JJ, Insogna KL, Weir EC, Broadus AE, Stewart AF (1987) Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase—stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. J Biol Chem 262:7151–7156
Dunbar ME, Wysolmerski JJ (1999) Parathyroid hormone–related protein: a developmental regulatory molecule necessary for mammary gland development. J Mammary Gland Biol Neoplasia 4:21–34
Kaiser SM, Sebag M, Rhim JS, Kremer R, Goltzman D (1994) Antisense-mediated inhibition of parathyroid hormone: related peptide (PTHrP) production in a keratinocyte cell line impedes differentiation. Mol Endocrinol 8:139–147
Datta NS, Abou-Samra AB (2009) PTH and PTHrP signaling in osteoblasts. Cell Signal 21(8):1245–1254
Lanske B, Kronenberg HM (1998) Parathyroid hormone: related peptide (PTHrP) and parathyroid hormone (PTH)/PTHrP receptor. Crit Rev Eukaryot Gene Expr 8(3–4):297–320
Hock JM, Fonseca J, Gunness-Hey M, Kemp BE, Martin TJ (1989) Comparison of the anabolic effects of synthetic parathyroid hormone–related protein (PTHrP) 1–34 and PTH(1–34) on bone in rats. Endocrinology 125:2022–2027
Weir EC, Terwilliger G, Sartori L, Insogna KL (1992) Synthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivo. Calcif Tissue Int 51:30–34
Horwitz MJ, Tedesco MB, Garcia-Ocaña A, Sereika SM, Prebehala L, Bisello A, Hollis BW, Gundberg CM, Stewart AF (2010) Parathyroid hormone: related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J Clin Endocrinol Metab 95(3):1279–1287
Hildreth BE 3rd, Werbeck JL, Thudi NK, Deng X, Rosol TJ, Toribio RE (2010) PTHrP 1–141 and 1–86 increase in vitro bone formation. J Surg Res 162(2):e9–e17
Wronski TJ, Cintrón M, Doherty AL, Dann LM (1988) Estrogen treatment prevents osteoporosis and depresses bone turnover in ovariectomized rats. Endocrinology 123(2):681–686
Cruess RL, Hong KC (1979) The effect of long term estrogen administration on bone metabolism in the female rat. Endocrinology 104(4):1188–1193
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have stated that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Xu, J., Rong, H., Ji, H. et al. Effects of Different Dosages of Parathyroid Hormone-Related Protein 1–34 on the Bone Metabolism of the Ovariectomized Rat Model of Osteoporosis. Calcif Tissue Int 93, 276–287 (2013). https://doi.org/10.1007/s00223-013-9755-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-013-9755-1